International projects implemented at SUM:
(akronim INNODIA)
Project carried out as part of the international program Innovative Medicines Initiative (IMI)
Project implementation period: November 1st, 2015 – October 10th, 2023
Content-related project manager at SUM: Przemysława Jarosz-Chobot , PhD, Professor (Head of the Department of Children’s Diabetology, Faculty of Medical Sciences in Katowice)
About the project:
Innovative Medicines Initiative (IMI) is a biomedical research program operating based on a public-private partnership, which is a form of cooperation between the European Commission and the pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). The project consortium consists of 40 institutions.
The main goal of the INNODIA project is to create a unique clinical database and biobank of patients at high risk of developing type 1 diabetes and newly diagnosed type 1 diabetes, which will allow studying the relationship between the decrease in pancreatic beta cell function and immunophenotype, genotype and new biomarkers.
Project partners:
- Medical University of Graz, Graz, Austria
- Katholieke Universiteit Leuven UZ Gasthuisberg, Leuven, Belgium
- Université Libre de Bruxelles – Hôpital Erasme, Brussels, Belgium
- Kobenhavns Universitet, Copenhagen, Denmark
- Herlev University Hospital, Region Hovedstaden, Herlev, Denmark
- Helsingin yliopisto (University of Helsinki – UH), Helsinki, Finland
- Oulun Yliopisto - Department of Paediatrics, Oulu, Finland
- Turun Yliopisto (University of Turku), Turku, Finland
- Institut National de la Santé et de la Recherche Médicale, Paris, France
- Stichting Katholieke Universiteit (Radboud University Medical Centre), Nijmegen, the Netherlands
- Academisch Ziekenhuis Leiden - Leids Universitair Medisch Centrum, Leiden, the Netherlands
- Hannoversche Kinderheilanstalt, Hannover , Germany
- Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH, Munich, Germany
- Technische Universitat Dresden, Dresden, Germany
- Universität Ulm, Ulm , Germany
- I.R.C.C.S. Ospedale Pediatrico Bambino Gesù, Rome, Italy
- University of Siena, Siena, Italy
- Universita di Pisa, Pisa, Italy
- Vita-Salute San Rafaelle University, Milan, Italy
- Università degli Studi „Gabriele d'Annunzio”, Chieti-Pescara, Italy
- Centre Hospitalier de Luxembourg Clinique pediatrique Kannerklinik, Luxembourg
- Oslo Universitetssykehus HF, Oslo, Norway
- Śląski Uniwersytet Medyczny w Katowicach (Medical University of Silesia), Katowice, Poland
- Univerza v Ljubljani, Ljubljana, Slovenia
- Université de Lausanne, Lausanne, Switzerland
- Lund University, Lund, Sweden
- University of Cambridge, Cambridge, Great Britain
- King's College London, Londyn, Great Britain
- University of Oxford, Oxford, Great Britain
- Cardiff University, Cardiff, Great Britain
- University of Exeter, Exeter, Great Britain
- Sanofi, Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany
- Novo Nordisk A/S, Gentofte, Denmark
- Eli Lilly and Company Ltd, Hampshire, Great Britain
- Glaxosmithkline Research and Development LTD, Stevenage, Great Britain
- Imcyse SA, Liège, Belgium
- Novartis, Basel, Switzerland
- Univercell-Biosolutions, Paris, France
- JDRF, New York, United States
- HCT, New York, United States
Contact:
Department of Children’s Diabetology
Faculty of Medical Sciences in Katowice
Medical University of Silesia
40752 Katowice, Poland
16 Medyków Str.
Phone no: (+48) 665 324 395
e-mail: innodia@sum.edu.pl
Related links: https://www.innodia.eu/pl/
(akronim INNODIA Harvest)
Project carried out as part of the international program Innovative Medicines Initiative (IMI)
Project implementation period: May 1st, 2020 – March 31st, 2024
Content-related project manager at SUM: Przemysława Jarosz-Chobot , PhD, Professor (Head of the Department of Children’s Diabetology, Faculty of Medical Sciences in Katowice)
About the project:
The INNODIA project, implemented at the Department of Children’s Diabetology, aims to create a unique clinical database and biobank of patients at high risk of developing type 1 diabetes (T1D) and patients with newly diagnosed T1D, which will allow studying the relationship between the decrease in pancreatic beta cell function and the immunophenotype, genotype and new biomarkers. The research is conducted by a consortium formed by 40 partners, including the Medical University of Silesia in Katowice represented by a team of employees of the Department of Children’s Diabetology, Faculty of Medical Sciences in Katowice, under the leadership of Przemysława Jarosz-Chobot , PhD, Professor.
As part of the research network established in recent years, research related to the INNODIA Harvest project is also proposed, the purpose of which is to summarize the observations and results achieved so far in connection with the implementation of the INNODIA project. Project " Translational approaches to disease modifying therapy of type 1 diabetes – HARVESTing the fruits of INNODIA" will enable its extension to experimental and clinical studies implementing new strategies to inhibit the progression of the disease to clinical type 1 diabetes in non-affected patients who have positive antibodies associated with type 1 diabetes destruction of pancreatic beta cells.
The grant agreement was concluded as part of the winning the 19th competition of the Innovative Medicines Initiative (IMI2 JU) (H2020-JTI-IMI2-2019-19-single-stage). The project started on May 1st, 2020 and will last three years.
As with the INNODIA project, the voice of people living with diabetes and their families will be at the heart of INNODIA Harvest, so that the process of implementing new research results and making breakthrough changes in the treatment of the disease is patient-centred.
Project partners:
- Katholieke Universiteit Leuven, Leuven, Belgium
- The Chancellor, Masters and Scholars of the University of Cambridge, Cambridge, United Kingdom
- Medical University of Graz, Austria
- University Libre de Bruxelles, Belgium
- Kobenhavns University, Copenhagen, Denmark
- Hovedstaden Region, Hillerød, Denmark
- Institut National de la Sante et de la Recherche Medicale, France
- Helsingin Yliopisto, Helsinki, Finland
- Oulun Yliopisto, Oulu, Finland
- Turku University, Turku, Finland
- Hannoversche Kinderheilanstalt, Hannover, Germany
- Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany
- Technische Universitat Dresden, Dresden, Germany
- ULM University, Germany
- Università degli Studi di Siena, Siena, Italy
- Università degli Studi 'G.d'Annunzio', Chieti-Pescara, Chieti, Italy
- University of Pisa, Pisa, Italy
- Center Hospitalier de Luxembourg, Luxembourg, Luxembourg
- University of Exeter, Exeter, United Kingdom
- Medical University of Silesia in Katowice, Katowice, Poland
- University of Ljubljana, Ljubljana, Slovenia
- University of Lausanne, Lausanne, Switzerland
- Stichting Katholieke Universiteit, Nijmegen, Netherlands
- Academisch Ziekenhuis Leiden, Leiden, Netherlands
- King's College London, London, United Kingdom
- Lunds University, Lund, Sweden
- Univercell Biosolutions Sas, Toulouse, France
- Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany
- Novo Nordisk, Denmark
- Glaxosmithkline Research and Development LTD, Brentford, United Kingdom
- Eli Lilly and Company Ltd, Hampshire, United Kingdom
- JDRF International, New York, United States
- The Helmsley Charitable Trust, New York
- Oslo Universitetssykehus, Oslo, Norway
- Chancellor, Masters and Scholars of the University of Oxford, Oxford, United Kingdom
- Cardiff University, Cardiff, United Kingdom
- University of Vita-Salute San Raffaele, Milano, Italy
- Novartis Pharma, Basel, Switzerland
- Imcyse S.A., Belgium
- Ospedale Pediatrico Bambino Gesu, Italy
Related links: https://www.innodia.eu/pl/harvest/
(akronim: StratKIT+)
Project carried out as part of the international program Interreg Baltic Sea Region
Project implementation period: October 1st, 2022 – March 31st, 2024 (18 months)
Content-related project manager at SUM: Katarzyna Brukało, PhD (Department of Health Policy, Faculty of Health Sciences in Bytom)
About the project:
The goal of the project is to further expand the toolkit for sustainable meals funded from public budgets (implemented as part of the StratKIT project) by adding new tools (possible small pilot activities), extending the network to other countries of the Baltic Sea Region - Sweden, Latvia and Lithuania. The activities will be included in one Work Package, which will include the following elements:
- comprehensive management and communication,
- searching for innovative ecological solutions to propose new tools,
- promoting and strengthening the network of sustainable public meals,
- the possibility of piloting existing and new tools,
- adding new tools to the toolbox on sustainable public meals and translating them into national languages,
- dissemination of the project in social media,
- activities and clustering with other related projects.
Thanks to the project, the activities of the partners in the field of circular economy regarding a sustainable meal funded from public budgets will be promoted both nationally and internationally.
Related links:
https://www.stratkit.eu/pl/projekt
https://www.linkedin.com/company/sustainable-public-meal-toolkit/
